Abstract Details

Title Assessment of Relative Importance of Disease Modifying Treatment (DMT) Attributes in Multiple Sclerosis (MS) Patients

Topic Multiple Sclerosis

Presentation(s) P2 - (-)

Poster/Presentation
Number 366

Objective

Background

Design/Methods

Results

Conclusions

Authors/Disclosures
Tobias Sejbaek, MD, PhD (Esbjerg Hospital) PRESENTER	Prof. Sejbaek has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Biogen, Merck, NeuroXpharm, Novartis, Roche, Sandoz and Sanofi. The institution of Prof. Sejbaek has received research support from Merck, Novartis, Roche and Sanofi.
	No disclosure on file
Jens Leander	No disclosure on file
Klaus G. Madsen	No disclosure on file

��ɫ��